Please login to the form below
Sosei Heptares
This page shows the latest Sosei Heptares news and features for those working in and with pharma, biotech and healthcare.
Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance
Targeting largest family of proteins in cell membranes. Sosei Heptares has enticed another big biopharma company to sign up to its G-protein coupled receptor (GPCR) drug discovery platform. ... Sosei Heptares has developed considerable expertise in GPCRs
Latest news
-
Pfizer’s alliance with Sosei Heptares bears first fruit
The specific targets remain under wraps for now, although Sosei Heptares says they address metabolic and inflammatory diseases. ... The company was officially rebranded Sosei Heptares last December, but is still operating largely independently as a wholly
-
Pfizer signs high-level deal with GPCR specialist Heptares
Pfizer's strategic-level deal with Sosei subsidiary Heptares will see the UK firm apply its technologies to engineer stabilised target GPCR proteins - selected by Pfizer - that will be used to ... biologics drugs - and will pay up to $189m per project to
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Where next in Alzheimer’s disease R&D?
Whereas in the past the sector had “a very singular focus on amyloid”, Sosei Heptares’ chief R&D officer Malcolm Weir said he now thinks it is looking at targets “in ... Other groups, including Sosei Heptares, are working on novel ways to modify
-
Deal Watch March 2017
rights to Heptares’ G protein-coupled receptor product for pain relief. ... 20. Heptares/ Sosei Group. Daiichi Sankyo. Licence. G protein coupled receptor for pain relief.
-
Pharma deals in August 2015
Not disclosed. Staying in oncology, AstraZeneca closed an exclusive global licence with Heptares [owned by Sosei] securing a headline value of $510m. ... Acquisition–asset. 570. Heptares [Sosei]. AZ. HTL 1071 immuno‐oncology small molecule and other
-
Medius Deal Watch table for February 2015
Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc.
More from intelligence
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Metrion Biosciences adds to its board
Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- FDA approves Roche’s Actemra COVID-19 trial
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
